Keystone Symposia

October 29-November 1, 2017
Santa Fe, USA
Giovanni Salerno, GARDP Head of Transversal Programmes, presented on the antibiotic memory recovery initiative.


X National Congress of Tropical Medicine and International Health

October 23-25, 2017
Bilbao, Spain
Representatives from DNDi and GARDP took part in the event.

STI & HIV World Congress

July 9-12, 2017
Rio de Janeiro, Brazil
Manica Balasegaram, GARDP’s Director, presented to and participated in, the round table at the event.

ASM Microbe 2017

June 1-5, 2017
New Orleans, USA
Manica Balasegaram, GARDP’s Executive Director, presented on antibiotics at the event.

Solutions for Drug-Resistant Infections

3-5 April, 2017
Brisbane, Australia
Jean-Pierre Paccaud, Business Development Director at Global Antibiotic R&D Partnership (GARDP), DNDi presented on antimicrobial resistance.

Neonatal Sepsis Expert Meeting

2-3 August, 2016
Geneva, Switzerland
A joint WHO-DNDi Global Antibiotic Research and Development Partnership (GARDP) event which was organized to review and evaluate an important NeoAMR proposal and to form a consensus on the way forward.

Gonorrhoea Expert Meeting

27-28 June, 2016
Geneva, Switzerland
This one day meeting with 26 participants from all around the world reviewed and evaluated the needs, progress and development of new and effective treatment options for gonorrhea.

Global Antibiotic R&D Partnership (GARDP) Launch Event

24 May, 2016
Geneva, Switzerland
This event launched the Global Antibiotic R&D Partnership (GARDP), a joint WHO/DNDi initiative incubated by DNDi in support of the Global Action Plan for Antimicrobial Resistance. GARDP aims to develop new antibiotic treatments, promote responsible use, and ensure access for all.

Global Antibiotic R&D Partnership (GARDP) Scientific Consultation

29 February, 2016
Institut Pasteur, Paris, France
The aim of this initial scientific consultation was to help GARD evolve from the initial scientific strategy articulated in the initial and revised GARD concept notes, determine priority areas and short- to medium-term projects to be launched within one year. Longer-term (upstream) projects will also be considered as GARD builds its R&D pipeline.